Acumen Pharmaceuticals, Inc.
Business
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing sabirnetug, a recombinant humanized monoclonal antibody targeting soluble amyloid-beta oligomers for the treatment of Alzheimer's disease. The company's lead program, sabirnetug (ACU193), is in Phase 2 clinical development (ALTITUDE-AD trial) with top-line results expected in late 2026, following positive Phase 1 proof-of-mechanism data. Acumen is also advancing an Enhanced Brain Delivery (EBD) technology platform through a collaboration with JCR Pharmaceuticals and developing a subcutaneous formulation of sabirnetug in partnership with Halozyme. The company operates as a single integrated business focused on neurodegenerative disease.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 105 | 94 | 42 | 32 | 12 | |
| General and administrative | 19 | 20 | 19 | 13 | 7 | |
| Total operating expenses | 124 | 114 | 61 | 45 | 20 | |
| Loss from operations | −124 | −114 | −61 | −45 | −20 | |
| Interest income | 7 | 14 | 11 | — | — | |
| Interest expense | −4 | −4 | −581,000 | — | — | |
| Change in fair value of embedded derivatives | −460,000 | 2 | −1 | 0 | — | |
| Other expense, net | −266,000 | −151,000 | −83,000 | −11,000 | 51,000 | |
| Total other income | 2 | 12 | 9 | 2 | −81 | |
| Net loss | −121 | −102 | −52 | −43 | −101 | |
| Unrealized gain (loss) on marketable securities | 131,000 | −360,000 | 1 | −520,000 | −231,000 | |
| Comprehensive loss | −121 | −103 | −51 | −43 | −101 | |
| Net loss per common share, basic (in dollars per share) | −2 | −1.71 | −1.08 | −1.06 | −5.02 | |
| Net loss per common share, diluted (in dollars per share) | −2 | −1.71 | −1.08 | −1.06 | −5.02 | |
| Weighted-average shares outstanding, basic (in shares) | 61 | 60 | 49 | 41 | 20 | |
| Weighted-average shares outstanding diluted (in shares) | 61 | 60 | 49 | 41 | 20 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 54 | 36 | 67 | 130 | 122 | |
| Marketable securities, short-term | 63 | 136 | 177 | 48 | 72 | |
| Prepaid expenses and other current assets | 5 | 7 | 3 | 3 | 4 | |
| Total current assets | 122 | 178 | 247 | 180 | 199 | |
| Marketable securities, long-term | 0 | 60 | 63 | 16 | 32 | |
| Restricted cash | 231,000 | 232,000 | — | — | — | |
| Other assets, long-term | 350,000 | 486,000 | 724,000 | 151,000 | 14,000 | |
| Total assets | 123 | 239 | 310 | 197 | 230 | |
| Accounts payable | 554,000 | 6 | 1 | 2 | 1 | |
| Accrued clinical trial expenses | 11 | 15 | 4 | 3 | 147,000 | |
| Accrued expenses and other current liabilities | 10 | 7 | 6 | 3 | — | |
| Debt, short-term | 9 | 0 | — | — | — | |
| Total current liabilities | 30 | 28 | 13 | 8 | 5 | |
| Debt, long-term | 22 | 29 | 30 | 0 | — | |
| Other liabilities, long-term | 0 | 150,000 | 284,000 | — | — | |
| Total liabilities | 52 | 57 | 43 | 8 | 5 | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024; 60,575,369 and 60,094,083 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 6,000 | 6,000 | 6,000 | 4,000 | 4,000 | |
| Additional paid-in capital | 517 | 507 | 489 | 360 | 353 | |
| Accumulated deficit | −447 | −325 | −223 | −170 | −128 | |
| Accumulated other comprehensive income (loss) | 83,000 | −48,000 | 312,000 | −751,000 | — | |
| Total stockholders equity | 70 | 182 | 267 | 189 | 225 | |
| Total liabilities and stockholders equity | 123 | 239 | 310 | 197 | 230 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 58,000 | 63,000 | 61,000 | 32,000 | 4,000 | |
| Stock-based compensation expense | 10 | 10 | 6 | 3 | 922,000 | |
| Amortization of premiums and accretion of discounts on marketable securities, net | −809,000 | −5 | −3 | 487,000 | 155,000 | |
| Amortization of right-of-use asset | 126,000 | 115,000 | 123,000 | 137,000 | 0 | |
| Realized gain on marketable securities | −59,000 | −97,000 | −11,000 | 0 | — | |
| Noncash interest expense | 1 | 1 | 145,000 | 0 | — | |
| Other noncash expense | 0 | 232,000 | 0 | 0 | 109,000 | |
| Prepaid expenses and other current assets | 1 | −4 | −369,000 | 2 | −4 | |
| Other long-term assets | 40,000 | 74,000 | −70,000 | −137,000 | −14,000 | |
| Accounts payable | −5 | 4 | −261,000 | 552,000 | 557,000 | |
| Accrued clinical trial expenses | −5 | 11 | 2 | 3 | 147,000 | |
| Accrued expenses and other liabilities | 3 | 32,000 | 3 | −562,000 | 3 | |
| Finance lease liability | 0 | −23,000 | 17,000 | 0 | — | |
| Net cash used in operating activities | −116 | −86 | −43 | −35 | −18 | |
| Purchases of marketable securities | −38 | −171 | −251 | −42 | −104 | |
| Proceeds from maturities and sales of marketable securities | 172 | 219 | 79 | 81 | 0 | |
| Purchases of property and equipment | −88,000 | −16,000 | −21,000 | −161,000 | −40,000 | |
| Net cash provided by investing activities | 134 | 48 | −172 | 39 | −104 | |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 8 | 122 | 4 | 169 | |
| Proceeds from exercise of stock options | 39,000 | 0 | 325,000 | 115,000 | 15,000 | |
| Payment for financing lease | 0 | −739,000 | 0 | — | — | |
| Payments for deferred offering costs | 0 | −230,000 | 0 | — | — | |
| Repurchase of common shares to pay employee withholding taxes | −73,000 | −41,000 | 0 | — | — | |
| Net cash (used in) provided by financing activities | −34,000 | 7 | 152 | 4 | 200 | |
| Net change in cash and cash equivalents and restricted cash | 18 | −31 | −63 | 8 | 78 | |
| Cash paid for income taxes | 0 | 0 | 0 | 0 | 0 | |
| Cash paid for interest | 3 | 3 | 169,000 | 0 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Acumen Pharmaceuticals, Inc.'s CIK number?
Acumen Pharmaceuticals, Inc.'s SEC CIK number is 0001576885 (1576885). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Acumen Pharmaceuticals, Inc.'s SEC filings?
All of Acumen Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Acumen Pharmaceuticals, Inc. last report earnings?
Acumen Pharmaceuticals, Inc. (ABOS) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-033868). This is Acumen Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Acumen Pharmaceuticals, Inc.'s most recent earnings 8-K?
Acumen Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001628280-26-033868. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Acumen Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →